Palisade Bio (PALI) Short Interest Ratio & Short Volume $1.75 -0.05 (-2.78%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Palisade Bio Short Interest DataPalisade Bio (PALI) has a short interest of 107,600 shares, representing 7.69% of the float (the number of shares available for trading by the public). This marks a -6.19% decrease in short interest from the previous month. The short interest ratio (days to cover) is 1.1, indicating that it would take 1.1 days of the average trading volume of 670,536 shares to cover all short positions.Current Short Interest107,600 sharesPrevious Short Interest114,700 sharesChange Vs. Previous Month-6.19%Dollar Volume Sold Short$264,696.00Short Interest Ratio1.1 Days to CoverLast Record DateNovember 30, 2024Outstanding Shares1,514,000 sharesFloat Size1,400,000 sharesShort Percent of Float7.69%Today's Trading Volume120,416 sharesAverage Trading Volume670,536 sharesToday's Volume Vs. Average18% Short Selling Palisade Bio? Sign up to receive the latest short interest report for Palisade Bio and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartPALI Short Interest Over TimePALI Days to Cover Over TimePALI Percentage of Float Shorted Over Time Ad Stansberry Research2025 could be “worse than the dot-com bust”, says man who predicted 2008 banking crisisDan is sharing his latest work with the public. Because what he's tracking right now, he says, is too serious to keep private.Click here to see Dan's full warning to the public. Palisade Bio Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 11/30/2024107,600 shares $264,696.00 -6.2%7.7%1.1 $2.46 11/15/2024114,700 shares $289,044.00 +166.1%8.8%1.4 $2.52 10/31/202443,100 shares $117,232.00 +158.1%3.3%0.6 $2.72 10/15/202416,700 shares $59,285.00 -30.1%1.4%0.3 $3.55 9/30/202423,900 shares $84,845.00 -57.4%2.1%0.4 $3.55 9/15/202456,100 shares $212,619.00 +13.3%4.8%0.9 $3.79 Get the Latest News and Ratings for PALI and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Palisade Bio and its competitors with MarketBeat's FREE daily newsletter. 8/31/202449,500 shares $174,735.00 -17.8%4.3%0.8 $3.53 8/15/202460,200 shares $223,342.00 -46.2%5.2%0.9 $3.71 7/31/2024111,900 shares $438,648.00 +105.0%12.2%1.6 $3.92 7/15/202454,600 shares $234,780.00 +129.4%6.0%0.1 $4.30 6/30/202423,800 shares $107,100.00 -12.2%2.6%0 $4.50 6/15/202427,100 shares $125,744.00 -10.0%3.0%0 $4.64 5/31/202430,100 shares $145,082.00 -14.5%3.3%0 $4.82 5/15/202435,200 shares $224,576.00 -80.3%3.8%0 $6.38 4/30/2024178,500 shares $1.08 million +417.4%21.3%0.2 $6.03 4/15/202434,500 shares $143,520.00 +1,816.7%4.1%0 $4.16 3/31/20241,800 shares $10,775.70 -96.0%N/A0 $5.99 3/15/202445,200 shares $16,294.60 -41.2%0.5%0 $0.36 2/29/202476,800 shares $30,873.60 -23.9%0.9%0 $0.40 2/15/2024100,900 shares $44,577.62 -95.0%1.1%0 $0.44 1/31/20242,000,000 shares $1.20 million +1,450.4%25.7%0.8 $0.60 1/15/2024129,000 shares $67,467.00 +1,915.6%1.5%0.7 $0.52 12/31/20236,400 shares $3,776.00 -76.0%0.1%0 $0.59 12/15/202326,700 shares $15,272.40 -23.5%0.3%0.2 $0.57 11/30/202334,900 shares $21,812.50 -47.6%0.4%0.2 $0.63 11/15/202366,600 shares $35,304.66 -52.2%0.8%0 $0.53 10/31/2023139,200 shares $77,256.00 -35.3%1.7%0 $0.56 10/15/2023215,100 shares $118,885.77 -7.9%2.6%0.1 $0.55 9/30/2023233,500 shares $135,897.00 -23.1%2.9%0.1 $0.58 9/15/2023303,600 shares $185,894.28 +74.9%3.7%0.1 $0.61 8/31/2023173,600 shares $118,360.48 +14.1%2.6%0.1 $0.68 8/15/2023152,200 shares $96,418.70 -27.6%2.3%0.4 $0.63 7/31/2023210,100 shares $474,826.00 -1.2%3.2%0.5 $2.26 7/15/2023212,700 shares $414,765.00 +342.2%3.2%0.6 $1.95 6/30/202348,100 shares $81,770.00 -75.2%0.7%0.1 $1.70 6/15/2023194,100 shares $312,501.00 -25.8%3.0%0.1 $1.61 5/31/2023261,700 shares $345,444.00 +128.4%4.0%0.2 $1.32 5/15/2023114,600 shares $182,214.00 -65.0%1.8%0.1 $1.59 4/30/2023327,300 shares $520,407.00 +4.7%9.8%0.2 $1.59 4/15/2023312,600 shares $593,940.00 +195.7%10.2%0.2 $1.902025 could be “worse than the dot-com bust”, says man who predicted 2008 banking crisis (Ad)Dan is sharing his latest work with the public. Because what he's tracking right now, he says, is too serious to keep private.Click here to see Dan's full warning to the public. 3/31/2023105,700 shares $372,064.00 -30.7%3.8%0.1 $3.52 3/15/2023152,600 shares $302,148.00 -33.6%6.5%0.1 $1.98 2/28/2023229,700 shares $496,152.00 +23.5%11.1%0.1 $2.16 2/15/2023186,000 shares $444,540.00 +41.8%4.8%0.1 $2.39 1/31/2023131,200 shares $380,480.00 -38.1%3.5%0 $2.90 1/15/2023211,800 shares $565,506.00 +176.9%9.0%0.1 $2.67 12/30/202276,500 shares $397,800.00 -21.9%3.2%0 $5.20 12/15/202297,900 shares $224,191.00 -77.1%7.2%0.1 $2.29 11/30/2022428,000 shares $1.66 million +14,166.7%31.7%0.3 $3.89 11/15/20223,000 shares $200.10 -98.5%0.2%0 $0.07 10/31/2022204,500 shares $18,629.95 +11.4%0.3%0 $0.09 10/15/2022183,600 shares $17,423.64 -37.9%0.3%0 $0.09 9/30/2022295,400 shares $29,244.60 -68.9%0.5%0.1 $0.10 9/15/2022949,200 shares $142,380.00 +3.4%2.0%0.2 $0.15 8/31/2022918,300 shares $149,499.24 -58.6%6.4%0.3 $0.16 8/15/20222,220,000 shares $517,260.00 +213.6%11.4%1 $0.23 7/31/2022707,900 shares $273,532.56 +42.8%3.0%2.9 $0.39 7/15/2022495,700 shares $232,979.00 +8.8%2.1%2.2 $0.47 6/30/2022455,800 shares $185,966.40 +4.8%2.0%1.9 $0.41 6/15/2022435,000 shares $208,147.50 -0.7%2.2%1.3 $0.48 5/31/2022438,100 shares $229,126.30 -9.1%2.2%0.3 $0.52 5/15/2022481,800 shares $243,549.90 -59.5%2.5%0.3 $0.51 4/30/20221,190,000 shares $928,200.00 +0.9%7.4%0.7 $0.78 4/15/20221,180,000 shares $1.10 million -10.6%7.3%0.6 $0.93 3/31/20221,320,000 shares $1.40 million +1,101.1%8.4%0.6 $1.06 3/15/2022109,900 shares $129,682.00 +67.5%0.9%0.1 $1.18 2/28/202265,600 shares $60,352.00 -43.7%0.6%0.1 $0.92 2/15/2022116,600 shares $115,445.66 -34.8%1.0%0.2 $0.99 1/31/2022178,900 shares $214,680.00 +5.7%1.5%0.2 $1.20 1/15/2022169,200 shares $219,960.00 +50.8%1.4%0.9 $1.30 12/31/2021112,200 shares $145,860.00 -23.3%1.0%0.6 $1.30 12/15/2021146,200 shares $279,242.00 -67.7%1.3%0.5 $1.91 11/30/2021453,000 shares $1.06 million -24.7%3.9%1.3 $2.33 11/15/2021601,900 shares $1.62 million +20.7%5.2%1.4 $2.69 10/29/2021498,800 shares $1.37 million +30.3%4.5%1.2 $2.74 10/15/2021382,900 shares $1.06 million -44.5%3.5%0.7 $2.76 9/30/2021690,300 shares $1.83 million +19.6%6.2%1.2 $2.65 9/15/2021577,400 shares $1.62 million +79.1%5.4%1 $2.80 8/31/2021322,400 shares $905,944.00 -12.9%3.4%0.6 $2.81 8/13/2021370,000 shares $962,000.00 No Change3.3%0.7 $2.60 PALI Short Interest - Frequently Asked Questions What is Palisade Bio's current short interest? Short interest is the volume of Palisade Bio shares that have been sold short but have not yet been closed out or covered. As of November 30th, investors have sold 107,600 shares of PALI short. 7.69% of Palisade Bio's shares are currently sold short. Learn More on Palisade Bio's current short interest. What is a good short interest ratio for Palisade Bio? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. PALI shares currently have a short interest ratio of 1.0. Learn More on Palisade Bio's short interest ratio. What is a good short interest percentage for Palisade Bio? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 7.69% of Palisade Bio's floating shares are currently sold short. Is Palisade Bio's short interest increasing or decreasing? Palisade Bio saw a decline in short interest in the month of November. As of November 30th, there was short interest totaling 107,600 shares, a decline of 6.2% from the previous total of 114,700 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Palisade Bio's float size? Palisade Bio currently has issued a total of 1,514,000 shares. Some of Palisade Bio's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Palisade Bio currently has a public float of 1,400,000 shares. How does Palisade Bio's short interest compare to its competitors? 7.69% of Palisade Bio's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Palisade Bio: Indaptus Therapeutics, Inc. (1.05%), Cyclerion Therapeutics, Inc. (38.16%), Mainz Biomed (5.53%), Eagle Pharmaceuticals, Inc. (2.90%), BioCardia, Inc. (2.92%), Vaccinex, Inc. (4.70%), Mustang Bio, Inc. (0.58%), RedHill Biopharma Ltd. (0.44%), Genprex, Inc. (5.43%), Brainstorm Cell Therapeutics Inc. (3.03%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.70 billion), Charter Communications, Inc. ($4.55 billion), Spotify Technology S.A. ($3.84 billion), Royal Caribbean Cruises Ltd. ($3.07 billion), International Paper ($3.00 billion), Coinbase Global, Inc. ($2.93 billion), Cencora, Inc. ($2.54 billion), Paychex, Inc. ($2.53 billion), SoFi Technologies, Inc. ($2.24 billion), and Reddit, Inc. ($2.00 billion). View all of the most shorted stocks. What does it mean to sell short Palisade Bio stock? Short selling PALI is an investing strategy that aims to generate trading profit from Palisade Bio as its price is falling. PALI shares are trading down $0.05 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Palisade Bio? A short squeeze for Palisade Bio occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of PALI, which in turn drives the price of the stock up even further. How often is Palisade Bio's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including PALI, twice per month. The most recent reporting period available is November, 30 2024. More Short Interest Resources from MarketBeat Related Companies Indaptus Therapeutics Short Interest Cyclerion Therapeutics Short Interest Mainz Biomed Short Interest Eagle Pharmaceuticals Short Interest BioCardia Short Interest Vaccinex Short Interest Mustang Bio Short Interest RedHill Biopharma Short Interest Genprex Short Interest Brainstorm Cell Therapeutics Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:PALI) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredTech funds are hemorrhaging cash: Sell this stock nowSomething very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palisade Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Palisade Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PALI Stock Alerts